Business Wire

TECHSTARS

30.6.2021 11:02:12 CEST | Business Wire | Press release

Share
Techstars partners with Alphabit Fund and Launchpool to bring blockchain-focused accelerator to London

Techstars , the worldwide network that helps entrepreneurs succeed, today announced a new accelerator program, the Launchpool Web3 Techstars Accelerator. The program will work with entrepreneurs building blockchain technology and tokenisation protocols driving towards the decentralised future of finance.

The program will run in partnership with Alphabit Fund, the first regulated cryptocurrency and digital asset investment fund, and Launchpool, a regulatory compliant investment platform that offers private seed guaranteed investment opportunities to its member community.

Techstars maintains notable experience and expertise in the blockchain space, with many strong blockchain companies in the Techstars portfolio including Chainalysis, who last week announced a $100 million round and valuation of $4.2 billion.

“Blockchain technology has the potential to shift the control of monetary value and information and disrupt global business processes, as the internet did in the early 2000s,” said Techstars General Manager Gagan Bhatia. “Working with Alphabit and the Launchpool community to support leading companies in this space is an incredible opportunity and an investment in the decentralised economy of the future.”

Located in London, the Launchpool Web3 Techstars Accelerator will work with ten startups each year over a three-month period where startups will receive funding, hands-on mentorship from Techstars, Alphabit, and Launchpool, access to curated workshops and resources, admittance to the Techstars global network for life, and exposure to a minimum viable community. Applications for the Launchpool Web3 Techstars Accelerator will open on September 13, 2021 and be accepted through December 1, 2021. The first year of the accelerator will operate from March 2022 through June 2022.

“Launchpool is thrilled to be partnering with Techstars and Alphabit to bring the Launchpool Web3 Techstars Accelerator to the crypto world. As firm believers in a multichain future, and being passionate about mainstream adoption, this first-of-its-kind accelerator is proud to be chain agnostic,” said Shane McQuillian, VP Strategy, Alphabit. “With a killer lineup of mentors that represent a diverse cross-section of the blockchain space to work together, we feel we can really help founders and BUIDLers bring something truly innovative to the wider crypto industry.”

Startups interested in the program are encouraged to learn more by visiting the Launchpool Web3 Techstars Accelerator page or expressing interest here . Corporations and investors interested in partnership opportunities with Techstars can get in touch with Will Robinson , SVP of Global Sales, or learn more at techstars.com/corporations .

About Techstars

The Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas—entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now we are on a mission to enable every person on the planet to contribute to, and benefit from, the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, we do this by connecting startups, investors, corporations, and cities to help build thriving startup communities. Techstars has invested in more than 2,500 companies with a combined market cap of more than $200B. www.techstars.com

About Alphabit

One of the first regulated crypto asset funds, Alphabit has forged a reputation for investing in companies at the cutting edge of the blockchain revolution. Alphabit believes, supports, and invests in the decentralised economy of the future, with a generous portfolio of startups, protocols, and DeFi solutions that address an alternative to the traditional financial systems. www.alphabit.fund

About Launchpool

LaunchPool is a regulatory compliant initiative which was started in 2020, by the Alphabit Digital Currency Fund with the aim of providing fair guaranteed access to early stages of project raises to the retail community. With the ethos of ‘Egalitarian Investment’, Launchpool counts over 35,000 investors across the world who believe in the idea of being your own VC, while supporting the startups ecosystem with a minimum viable community, resources, access to funding opportunities, and enabling partnerships across the blockchain ecosystem. www.launchpool.xyz

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye